Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 344

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 344
---
 change of method on defined benefit obligation and the income statement to be insignificant, these impacts have not been restated for years prior to January 1, 2021. The effects of this change of method are therefore taken into account retrospectively as of January 1, 2021 in respect of 2020's and prior years defined benefit obligation. The adjustment at that date corresponds to a reduction in the 2020 commitments in the amount of €1,054thousand. This reversal has been offset against previous reserves and retained earnings.

There is no asset covering the defined benefit obligations.

An increase/decrease of +/- 25 basis point of the discount rate would result in a decrease/increase of the total benefit obligation of € 65

The actuarial assumptions used for the provision for length-of-service awards are as follows:

•Discount rate: 3.00

•Annual rate of salary increase: 2.50

•Rate of employer contributions: 49.29

•Employee contributions: 22.62

•Retirement age: 64 62

•Mortality table: TH-TF 00-02

•Annual mobility rate: 5.70

The amounts recognized as an expense linked to defined contributions plans amounted to € 1,432 1,283 1,251

11)Share capital and share based payments

a) Share capital

The Company manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to shareholders through the optimization of the debt and equity balance.

The Company has never declared or paid any dividends on its ordinary shares. The Company does not anticipate paying cash dividends on its equity securities in the foreseeable future and intend to retain all available funds and any future earnings for use in the operation and expansion of its business, given our state of development.

F-48

As of December 31, 2024, the Company’s share capital amounted to € 4,192,221 83,830,336 0.05 6,494 0.05 7,581 0.05

Share capital does not include BSAs, BSAAR, AGAs and AGAPs that have been granted to certain investors or natural persons, both employees and non-employees of the Company, but not yet exercised.

In October 21, 2019 and December 30, 2019, the retention period for the “2016 free preferred shares” has ended. The number of ordinary shares